Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma

Xavier Leleu • 10 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Daratumumab Dexamethasone Ixazomib
IFM 2018-02

Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, comments on the toxicity of dexamethasone and discusses the results of IFM 2018-02 (NCT03757221), a Phase II study assessing the safety and efficacy of ixazomib plus daratumumab without dexamethasone in elderly and frail patients with relapsed/refractory (R/R) multiple myeloma. Overall, the study suggested that this combination has a favorable efficacy profile and improved safety in comparison to dexamethasone-based regimens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Janssen, Takeda, BMS, GSK

More from Xavier Leleu

Quadruplet regimens in transplant-ineligible NDMM: the new standard of care 3:19
Quadruplet regimens in transplant-ineligible NDMM: the new standard of care
Xavier Leleu • 17 Sep 2025
The IRAKLIA trial: isatuximab subcutaneous via OBI versus IV in RRMM 2:58
The IRAKLIA trial: isatuximab subcutaneous via OBI versus IV in RRMM
Xavier Leleu • 17 Sep 2025
The efficacy and safety of belantamab mafodotin in R/R myeloma treated in the real-world setting 4:41
The efficacy and safety of belantamab mafodotin in R/R myeloma treated in the real-world setting
Xavier Leleu • 8 Dec 2024
HRQoL in patients receiving Isa-VRd versus VRd alone in the IMROZ trial 4:25
HRQoL in patients receiving Isa-VRd versus VRd alone in the IMROZ trial
Xavier Leleu • 8 Dec 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals